1 enrolling by invitation. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Dermatomyositis: new trials by email Literature Review of Dermatomyositis trials Research Report on Dermatomyositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Efgartigimod PH20 SC - Myositis, Active Idiopathic Inflammatory Myopathy | Phase 3 | Enrolling by invitation | argenx | 240 | 2023-09-12 | 2026-10-16 |
Antisynthetase syndrome (1) · Myositis (1) · Polymyositis (1)
Connective Tissue Diseases (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
argenx (1)
Argentina (1) · Austria (1) · Belgium (1) · Bulgaria (1) · China (1) · Cyprus (1) · Czechia (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Ireland (1) · Italy (1) · Japan (1)